Research Progress of Ruxolitinib in the Treatment of Vitiligo
LI Zhaoyu
ZHANG Hongying
Abstract：Vitiligo is an autoimmune skin disease caused by abnormal function of melanocytes in white spots.The pathogenesis of vitiligo is still unclear.Current research has found that the Janus kinase-signal transducer and activator of transcription(JAK-STAT)signaling pathway is involved in the pathogenesis of vitiligo.Ruxolitinib is a typical JAK inhibitor that mainly acts on the JAK-STAT signaling pathway and plays an important role in inhibiting inflammation,and regulating immune and hematopoietic function.Domestic and foreign studies have shown that ruxolitinib has clear efficacy in skin diseases,such as atopic dermatitis and alopecia areata,showing good application prospects in the treatment of vitiligo.This article mainly summarized the latest research progress of ruxolitinib in the treatment of vitiligo.
Keywords：RuxolitinibVitiligoTyrosine protein kinaseTransduction factors and transcriptional activators
Publication Date：2025-01-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 273-276 )